Medisus Pharma

CRIKZO 250MG (Crizotinib) is a prescription-only, anti-cancer medication manufactured by Hetero Healthcare Limited. It is used to treat a specific type of non-small cell lung cancer (NSCLC) that has spread to nearby areas or other parts of the body. 

OXALOVID degradation by the anaerobic bacterium Oxalobacter formigenes is important for human health, helping to prevent hyperoxaluria and disorders such as the development of kidney stones.

Tukavo 150mg is a brand name for the targeted cancer drug Tucatinib, a tyrosine kinase inhibitor (TKI) used to treat HER2-positive breast cancer that has spread (metastatic), including to the brain, often with trastuzumab and capecitabine. It works by blocking the HER2 protein that cancer cells need to grow, slowing or stopping its spread, and is a targeted therapy, not chemotherapy. Common side effects can include diarrhea, fatigue, mouth sores, and nausea. 

The Abirapro 250mg tablet is a prescription anti-cancer medication used in adult men to treat advanced prostate cancer that has spread to other parts of the body (metastatic cancer). It is a form of hormonal therapy, not traditional chemotherapy. 

HERTAB 250 (Lapatinib 250mg) is an anti-cancer tablet used for advanced breast cancer, working by blocking HER2 protein growth to stop cancer cell multiplication, often with other drugs like Capecitabine; common side effects include diarrhea, nausea, fatigue, and skin issues, requiring doctor monitoring for heart/liver/lung function, and it's crucial to avoid if pregnant/breastfeeding. 

The Rexigo 120 mg tablet is a prescription medication containing the active ingredient Relugolix, primarily used to treat adults with advanced hormone-sensitive prostate cancer. It belongs to a class of drugs known as gonadotropin-releasing hormone (GnRH) receptor antagonists.